LT3626270T - Širdies ir kraujagyslių ligų gydymas - Google Patents

Širdies ir kraujagyslių ligų gydymas

Info

Publication number
LT3626270T
LT3626270T LTEP19202854.6T LT19202854T LT3626270T LT 3626270 T LT3626270 T LT 3626270T LT 19202854 T LT19202854 T LT 19202854T LT 3626270 T LT3626270 T LT 3626270T
Authority
LT
Lithuania
Prior art keywords
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
LTEP19202854.6T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond RIZKALA
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3626270(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LT3626270T publication Critical patent/LT3626270T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
LTEP19202854.6T 2013-08-26 2014-08-26 Širdies ir kraujagyslių ligų gydymas LT3626270T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31

Publications (1)

Publication Number Publication Date
LT3626270T true LT3626270T (lt) 2024-01-25

Family

ID=51494327

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP14761702.1T LT3038654T (lt) 2013-08-26 2014-08-26 Naujas panaudojimas
LTEP19202854.6T LT3626270T (lt) 2013-08-26 2014-08-26 Širdies ir kraujagyslių ligų gydymas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP14761702.1T LT3038654T (lt) 2013-08-26 2014-08-26 Naujas panaudojimas

Country Status (15)

Country Link
US (2) US20160213646A1 (lt)
EP (3) EP3626270B1 (lt)
JP (1) JP6097888B2 (lt)
CY (1) CY1122531T1 (lt)
DK (2) DK3626270T3 (lt)
ES (2) ES2968541T3 (lt)
FI (1) FI3626270T3 (lt)
HR (2) HRP20240034T1 (lt)
HU (2) HUE064634T2 (lt)
LT (2) LT3038654T (lt)
PL (2) PL3038654T3 (lt)
PT (2) PT3038654T (lt)
RS (2) RS59816B1 (lt)
SI (2) SI3626270T1 (lt)
WO (1) WO2015028941A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016125123A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
US20180140579A1 (en) * 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
US20190054069A1 (en) 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
WO2021052441A1 (zh) * 2019-09-20 2021-03-25 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
IL130599A0 (en) * 1997-01-10 2000-06-01 Merck & Co Inc Use of angiotensin II antagonists to treat symptomatic heart failure
CN1615134A (zh) 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
MXPA05012299A (es) * 2003-05-16 2006-01-30 Novartis Ag Composicion farmaceutica que comprende valsartan.
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
HUE024872T2 (en) 2008-11-22 2016-02-29 Hoffmann La Roche Use of anti-vegf antibody in combination with chemotherapy to treat breast cancer
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use

Also Published As

Publication number Publication date
PT3626270T (pt) 2024-01-11
DK3626270T3 (da) 2024-01-15
CY1122531T1 (el) 2021-01-27
RS65037B1 (sr) 2024-02-29
HRP20240034T1 (hr) 2024-03-29
EP3038654A1 (en) 2016-07-06
HRP20200060T1 (hr) 2020-04-03
JP6097888B2 (ja) 2017-03-15
FI3626270T3 (fi) 2024-01-11
EP3626270A1 (en) 2020-03-25
HUE047186T2 (hu) 2020-04-28
EP3626270B1 (en) 2023-10-11
JP2016528303A (ja) 2016-09-15
EP3038654B1 (en) 2019-10-30
PT3038654T (pt) 2020-02-04
SI3038654T1 (sl) 2020-02-28
ES2968541T3 (es) 2024-05-10
RS59816B1 (sr) 2020-02-28
EP4321157A3 (en) 2024-05-15
DK3038654T3 (da) 2020-02-03
US20160213646A1 (en) 2016-07-28
US20210077461A1 (en) 2021-03-18
ES2767084T3 (es) 2020-06-16
EP4321157A2 (en) 2024-02-14
WO2015028941A1 (en) 2015-03-05
SI3626270T1 (sl) 2024-03-29
HUE064634T2 (hu) 2024-04-28
LT3038654T (lt) 2020-01-27
PL3038654T3 (pl) 2020-05-18
PL3626270T3 (pl) 2024-04-08

Similar Documents

Publication Publication Date Title
IL287516A (en) Medicinal uses of empagliflozin
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HK1219236A1 (zh) 猝倒的治療
HK1213818A1 (zh) 依帕列淨的治療用途
FI3626270T3 (fi) Sydän- ja verisuonitautien hoito
PL2981271T3 (pl) Zastosowania terapeutyczne empagliflozyny
GB201403083D0 (en) Treatment of cancer
HK1220127A1 (zh) 自身免疫性疾病的治療
IL241096B (en) Treatment methods
HK1232118A1 (zh) 癌症的治療
GB201320014D0 (en) Treatment of cardiovascular disease
GB201321628D0 (en) Treatment of disease
GB201314303D0 (en) Treatment of HPV
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
GB201322778D0 (en) Method of treatment
GB201308529D0 (en) Treatment of cancer
GB201314882D0 (en) Method of treatment
GB201305020D0 (en) Treatment of cancer